{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:46:51Z","timestamp":1794433611008,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","award":["RS-2020-KH106434"],"award-info":[{"award-number":["RS-2020-KH106434"]}],"id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-02223212"],"award-info":[{"award-number":["RS-2025-02223212"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2019-NR040057"],"award-info":[{"award-number":["RS-2019-NR040057"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute of Information & Communications Technology Planning & Evaluation","award":["RS-2021-II212068"],"award-info":[{"award-number":["RS-2021-II212068"]}]},{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center, Sungkyunkwan University","doi-asserted-by":"publisher","award":["SMX1250081"],"award-info":[{"award-number":["SMX1250081"]}],"id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["2024-ER1003-01"],"award-info":[{"award-number":["2024-ER1003-01"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02077-6","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:55:04Z","timestamp":1779364504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Jehyun","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihwan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heekyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohyun","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heekyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ADNI study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"4","key":"2077_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2077_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25(1):59\u201370. https:\/\/doi.org\/10.1111\/ene.13439.","journal-title":"Eur J Neurol"},{"issue":"10","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367(10):885\u20137. https:\/\/doi.org\/10.1056\/NEJMp1208061.","journal-title":"N Engl J Med"},{"issue":"11","key":"2077_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer\u2019s disease concord with beta-amyloid PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2077_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther. 2020;12(1):36. https:\/\/doi.org\/10.1186\/s13195-020-00595-5.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"2077_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/acn3.51195","volume":"7","author":"J Reimand","year":"2020","unstructured":"Reimand J, Boon BDC, Collij LE, et al. Beta-amyloid PET and CSF in an autopsy-confirmed cohort. Ann Clin Transl Neurol. 2020;7(11):2150\u201360. https:\/\/doi.org\/10.1002\/acn3.51195.","journal-title":"Ann Clin Transl Neurol"},{"issue":"17","key":"2077_CR7","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"issue":"11","key":"2077_CR8","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of beta-amyloid but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"issue":"1","key":"2077_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2077_CR10","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(11):4967\u201377. https:\/\/doi.org\/10.1002\/alz.13026.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2077_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"5","key":"2077_CR12","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR, Kirmess KM, Eastwood S, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Abeta42\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024;20(5):3179\u201392. https:\/\/doi.org\/10.1002\/alz.13764.","journal-title":"Alzheimers Dement"},{"key":"2077_CR13","doi-asserted-by":"publisher","unstructured":"Niimi Y, Janelidze S, Sato K, et al. Combining plasma Abeta and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimers Res Ther. 2024;16(1):115. https:\/\/doi.org\/10.1186\/s13195-024-01469-w.","DOI":"10.1186\/s13195-024-01469-w"},{"issue":"2","key":"2077_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16049","volume":"31","author":"R Perneczky","year":"2024","unstructured":"Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti-amyloid antibody treatments for Alzheimer\u2019s disease. Eur J Neurol. 2024;31(2):e16049. https:\/\/doi.org\/10.1111\/ene.16049.","journal-title":"Eur J Neurol"},{"issue":"12","key":"2077_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905","volume":"21","author":"CH van Dyck","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K, et al. Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: results from the Clarity AD open-label extension study. Alzheimers Dement. 2025;21(12):e70905. https:\/\/doi.org\/10.1002\/alz.70905.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaneurol.2025.3869","volume":"82","author":"M Lu","year":"2025","unstructured":"Lu M, Kim MJ, Collins EC, et al. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA Neurol. 2025;82(12):1251\u20136. https:\/\/doi.org\/10.1001\/jamaneurol.2025.3869.","journal-title":"JAMA Neurol"},{"key":"2077_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.924550","volume":"14","author":"SH Kang","year":"2022","unstructured":"Kang SH, Kim JH, Chang Y, et al. Independent effect of body mass index variation on beta-amyloid positivity. Front Aging Neurosci. 2022;14:924550. https:\/\/doi.org\/10.3389\/fnagi.2022.924550.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314. https:\/\/doi.org\/10.1002\/alz.12787.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2077_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14368","volume":"21","author":"EH Lee","year":"2025","unstructured":"Lee EH, Kang SH, Shin D, et al. Plasma Alzheimer\u2019s disease biomarker variability: amyloid-independent and amyloid-dependent factors. Alzheimers Dement. 2025;21(1):e14368. https:\/\/doi.org\/10.1002\/alz.14368.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2077_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, et al. Plasma Abeta42\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19(4):1117\u201334. https:\/\/doi.org\/10.1002\/alz.12724.","journal-title":"Alzheimers Dement"},{"key":"2077_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106356","volume":"189","author":"AL Wojdala","year":"2023","unstructured":"Wojdala AL, Bellomo G, Gaetani L, et al. Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiol Dis. 2023;189:106356. https:\/\/doi.org\/10.1016\/j.nbd.2023.106356.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"2077_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.45862","volume":"8","author":"C Trieu","year":"2025","unstructured":"Trieu C, van Harten AC, van Leeuwenstijn M, et al. Longitudinal blood-based biomarkers and clinical progression in subjective cognitive decline. JAMA Netw Open. 2025;8(12):e2545862. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.45862.","journal-title":"JAMA Netw Open"},{"key":"2077_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","volume":"94","author":"MA Sugarman","year":"2020","unstructured":"Sugarman MA, Zetterberg H, Blennow K, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease. Neurobiol Aging. 2020;94:60\u201370. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.05.011.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"2077_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100724","volume":"6","author":"VR Varma","year":"2025","unstructured":"Varma VR, An Y, Kac PR, et al. Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer\u2019s disease. Med. 2025;6(9):100724. https:\/\/doi.org\/10.1016\/j.medj.2025.100724.","journal-title":"Med"},{"issue":"3","key":"2077_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cb3e25.","journal-title":"Neurology"},{"issue":"4","key":"2077_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.nic.2005.09.008","volume":"15","author":"SG Mueller","year":"2005","unstructured":"Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer\u2019s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4):869\u201377. https:\/\/doi.org\/10.1016\/j.nic.2005.09.008.","journal-title":"Neuroimaging Clin N Am"},{"issue":"7","key":"2077_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","volume":"11","author":"WJ Jagust","year":"2015","unstructured":"Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement. 2015;11(7):757\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.001.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2077_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578\u201386. https:\/\/doi.org\/10.1002\/ana.23650.","journal-title":"Ann Neurol"},{"issue":"4","key":"2077_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","volume":"8","author":"MJ Figurski","year":"2012","unstructured":"Figurski MJ, Walig\u00f3rska T, Toledo J, et al. Improved protocol for measurement of plasma \u03b2-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 2012;8(4):250\u201360. https:\/\/doi.org\/10.1016\/j.jalz.2012.01.001.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2077_CR30","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement. 2024;20(11):8074\u201396. https:\/\/doi.org\/10.1002\/alz.14315.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2077_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/jnnp.2010.231555","volume":"82","author":"LS Elias-Sonnenschein","year":"2011","unstructured":"Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1149\u201356. https:\/\/doi.org\/10.1136\/jnnp.2010.231555.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2077_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888\u201398. https:\/\/doi.org\/10.1016\/j.jalz.2019.04.001.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2077_CR33","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1002\/alz.13318","volume":"19","author":"Y Yakoub","year":"2023","unstructured":"Yakoub Y, Ashton NJ, Strikwerda-Brown C, et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(12):5620\u201331. https:\/\/doi.org\/10.1002\/alz.13318.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2077_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01401-2","volume":"16","author":"J Wu","year":"2024","unstructured":"Wu J, Xiao Z, Wang M, et al. The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study. Alzheimers Res Ther. 2024;16(1):32. https:\/\/doi.org\/10.1186\/s13195-024-01401-2.","journal-title":"Alzheimers Res Ther"},{"key":"2077_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1150510","volume":"15","author":"B Zhang","year":"2023","unstructured":"Zhang B, Zhang C, Wang Y, et al. Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer\u2019s disease. Front Aging Neurosci. 2023;15:1150510. https:\/\/doi.org\/10.3389\/fnagi.2023.1150510.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"2077_CR36","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1002\/alz.14073","volume":"20","author":"V Devanarayan","year":"2024","unstructured":"Devanarayan V, Doherty T, Charil A, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(8):5617\u201328. https:\/\/doi.org\/10.1002\/alz.14073.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2077_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14600","volume":"21","author":"L Karlsson","year":"2025","unstructured":"Karlsson L, Vogel J, Arvidsson I, et al. Machine learning prediction of tau-PET in Alzheimer\u2019s disease using plasma, MRI, and clinical data. Alzheimers Dement. 2025;21(2):e14600. https:\/\/doi.org\/10.1002\/alz.14600.","journal-title":"Alzheimers Dement"},{"key":"2077_CR38","doi-asserted-by":"publisher","unstructured":"Sanotra MR, Zeng X, Deek RA, et al. Combining\u00a0p\u2010tau217 with Other Blood Biomarkers to Enhance Prediction of Cognitive Decline: A Large Memory Clinic Cohort Study.\u00a0Alzheimers Dement. 2026;21(Suppl 2):e106988. Published 2026 Jan 8. https:\/\/doi.org\/10.1002\/alz70856_106988.","DOI":"10.1002\/alz70856_106988"},{"issue":"1","key":"2077_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66728-2","volume":"16","author":"M Valletta","year":"2025","unstructured":"Valletta M, Vetrano DL, Gregorio C, et al. Blood biomarkers of Alzheimer\u2019s disease and progression across different stages of cognitive decline in the community. Nat Commun. 2025;16(1):10412. https:\/\/doi.org\/10.1038\/s41467-025-66728-2.","journal-title":"Nat Commun"},{"issue":"2","key":"2077_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14508","volume":"21","author":"NJ Ashton","year":"2025","unstructured":"Ashton NJ, Keshavan A, Brum WS, et al. The Alzheimer\u2019s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. Alzheimers Dement. 2025;21(2):e14508. https:\/\/doi.org\/10.1002\/alz.14508.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2077_CR41","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","volume":"20","author":"WS Brum","year":"2024","unstructured":"Brum WS, Ashton NJ, Simr\u00e9n J, et al. Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimers Dement. 2024;20(2):1284\u201397. https:\/\/doi.org\/10.1002\/alz.13518.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02077-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:35:11Z","timestamp":1785108911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02077-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ADNI study was approved by the institutional review boards of all participating institutions. Written informed consent was obtained from all participants or their authorized representatives in accordance with the Declaration of Helsinki. Further details can be found at\n                      \n                      .","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sang Won Seo has served at scientific advisory boards and\/or as a consultant for Quanterix and Eli-Lilly. Sang Won Seo is co-founder of BeauBrain Healthcare Inc.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"170"}}